This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AngioDynamics' (ANGO) Q3 Earnings & Revenues Lag Estimates
by Zacks Equity Research
Despite strength in the VIT business, AngioDynamics (ANGO) exited third-quarter fiscal 2019 on a tepid note, with both earnings and revenues missing estimates.
Varian Announces Halcyon's First Successful Case in Malaysia
by Zacks Equity Research
Varian's (VAR) Halcyon is much superior to traditional technologies, thanks to the speed of treatment and improved quality of patient care it offers.
Nevro (NVRO) Plagued by Issues in Australia & Stiff Rivalry
by Zacks Equity Research
Nevro's (NVRO) international sales get affected by weakness in Australia.
Bio-Rad's Latest FDA Nod to Boost Clinical Diagnostics Arm
by Zacks Equity Research
The recent development will help Bio-Rad (BIO) rake in increased top-line contributions from the Clinical Diagnostics business.
Walgreens Boots (WBA) Q2 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
A difficult macroeconomic environment and market challenges made the fiscal second quarter the toughest since the formation of Walgreens Boots Alliance (WBA).
NuVasive (NUVA) Completes First COHERE XLIF Case in U.S.
by Zacks Equity Research
NuVasive's (NUVA) Advanced Materials Science implant portfolio will be fortified by the incorporation of the Porous PEEK technology into its implants for lateral single-position surgery.
Medtronic's Diabetes Arm Grows Strong, Rising Costs Ail
by Zacks Equity Research
Medtronic (MDT) is highly optimistic about its foray into the $1-billion standalone CGM market with its Guardian Connect.
Glaukos (GKOS) Banks on Solid Pipeline Amid Stiff Competition
by Zacks Equity Research
Glaukos' (GKOS) strong pipeline is indicative of brighter prospects ahead. However, cutthroat competition in the medical-device industry is worrisome.
AngioDynamics Gets FDA Nod to Begin NanoKnife DIRECT Study
by Zacks Equity Research
AngioDynamics' (ANGO) launches AngioDIRECT.com for enrolling participants as part of the DIRECT clinical study.
Amedisys Closes Oklahoma-Based RoseRock Healthcare Buyout
by Sriparna Ghosal
The acquisition of RoseRock Healthcare aligns with Amedisys' (AMED) strategy of foraying into the hospice care market of Oklahoma.
3 Reasons Why Investors Should Retain PerkinElmer (PKI) Stock
by Zacks Equity Research
PerkinElmer (PKI) has been gaining investor confidence on consistently positive results.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) is currently keeping well with its goals to strengthen foothold in the multi-billion gene sequencing market.
Here's Why You Should Invest in Smith & Nephew (SNN) Now
by Zacks Equity Research
Smith & Nephew (SNN) has been gaining investor confidence on consistently positive results.
Globus Medical Global Base Solid, Pricing Scenario Bothers
by Zacks Equity Research
Globus Medical (GMED) is upbeat about its growth prospects in the current and the emerging global markets through a continual expansion of direct and distributor sales forces.
Here's Why You Should Invest in ResMed (RMD) Stock Right Now
by Zacks Equity Research
ResMed (RMD) continues to invest and expand presence in high-growth markets like China, South Korea, India, Brazil and many countries in Eastern Europe.
Genomic Health's New Positive Data to Boost Test Uptake
by Zacks Equity Research
Genomic Health (GHDX) continues to see positive developments for Oncotype DX Breast Recurrence Score tests.
Neogen Hurt by Weakness in Animal Safety, Currency Woes
by Zacks Equity Research
Neogen (NEOG) exits fiscal third quarter on a disappointing note due to poor performance of Animal Safety segment.
QIAGEN Unveils Liquid Biopsy Workflows & Panels, Widens Suite
by Zacks Equity Research
QIAGEN (QGEN) is progressing well with its testing menu expansion strategy.
Here's Why You Should Hold on to STERIS (STE) Stock Now
by Zacks Equity Research
STERIS (STE) has been gaining investors' confidence on consistently positive results.
Myriad Genetics Gains on Innovation, New Reimbursements
by Zacks Equity Research
Myriad Genetics (MYGN) aims at raising revenues by commercializing its product suite that includes Vectra DA, Prolaris, myPath Melanoma, Companion Diagnostics, EndoPredict and myPlan Lung Cancer Test.
ResMed (RMD) Introduces ReSupply Solution, Expands in HME
by Zacks Equity Research
ResMed (RMD) claims ReSupply solution to improve patient response through growth in the long-term therapy adherence of those suffering sleep apnea.
Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock
by Zacks Equity Research
The innovation-based, multi-modality global strategy, enabled by enhanced commercial capability, accelerates IDEXX's (IDXX) recurring CAG Diagnostics revenue growth.
Baxter Showcases PN Product Portfolio at ASPEN Conference
by Zacks Equity Research
The launch of Clinolipid will be a crucial step toward Baxter's (BAX) goal of strengthening its lipid portfolio and offering enhanced health care to malnourished patients.
Bruker Consistently Gains From NANO & New Strategic Buyouts
by Zacks Equity Research
Bruker (BRKR) is progressing well with its three strategic buyouts, indicative of a majority interest in both Hain Diagnostics and Mestrelab along with the Alicona Imaging acquisition.
Medtronic Unveils MedTech Innovation Accelerator in China
by Zacks Equity Research
The MedTech Innovation Accelerator is a collaborative initiative on part of Medtronic (MDT) to foray into the Chinese med-tech innovation market via venture investments, incubation and acceleration.